Welcome to our dedicated page for 908 Devices SEC filings (Ticker: MASS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for 908 Devices Inc. (NASDAQ: MASS) provides access to the company’s official U.S. Securities and Exchange Commission disclosures, alongside AI-powered summaries that help explain the contents of each document. As an emerging growth company listed on The NASDAQ Global Market, 908 Devices files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, among other documents.
In its filings, 908 Devices reports financial performance and segment details related to its portfolio of purpose-built handheld devices for chemical analysis. Investors can review product revenue, service and contract revenue, OEM and funded partnership revenue, recurring revenue associated with its installed base, and information on cost of revenue, operating expenses and net income or loss from continuing operations. The company also discloses non-GAAP metrics such as adjusted gross profit, adjusted gross margin and adjusted EBITDA, along with reconciliations to the nearest GAAP measures.
Form 8-K filings highlight material events such as quarterly earnings releases and changes in the Board of Directors. For example, recent 8-Ks have furnished press releases announcing financial results for specific quarters and documented the resignation of a director and appointment of a new director with extensive experience in nuclear, chemical and biological defense programs. These filings also confirm the company’s listing details and emerging growth company status.
Through this page, users can also monitor equity and governance disclosures, including information on non-employee director compensation, stock option and incentive plans, and any future insider transaction reports on Form 4 when available. Stock Titan’s AI tools summarize lengthy filings, highlight key figures and definitions, and surface important changes in revenue composition, operating expenses, contingent consideration, restructuring charges and other items that affect 908 Devices’ financial profile.
By combining real-time EDGAR updates with plain-language AI explanations, this filings hub helps readers quickly understand how 908 Devices is performing, how it uses non-GAAP measures, and how governance and strategic decisions are reflected in its regulatory record.
908 Devices Inc. SVP John Kenneweg reported a routine equity compensation event involving vested performance stock units (PSUs) and a related tax sale. On May 1, 2026, 26,042 PSUs vested and were converted into 26,042 shares of Common Stock. To cover tax withholding obligations from this vesting, 7,787 shares of Common Stock were sold in an open-market “sell to cover” transaction at $6.83 per share, a sale mandated by the company’s election and described as non-discretionary for the insider. Following these transactions, Kenneweg directly holds 76,039 shares of Common Stock, and all of the reported PSUs have been fully settled.
Kenneweg John reported acquisition or exercise transactions in this Form 4 filing.
908 Devices Inc. reported that SVP of Sales & Product Marketing John Kenneweg received a grant of 26,042 Performance Stock Units. Each unit represents a contingent right to receive one share of Common Stock with a par value of $0.001 when it vests.
The compensation committee certified achievement of the required performance metrics and goals on April 28, 2026, and the PSUs are scheduled to vest on May 1, 2026 in accordance with their terms. The PSUs have no expiration date, and this filing reflects a compensation-related equity award rather than an open-market trade.
908 Devices Inc. is asking stockholders to vote at its 2026 Annual Meeting, held virtually on June 11, 2026 at 10:00 a.m. Eastern Time. The meeting will be online only via a webcast platform.
Stockholders will vote on electing three Class III directors to terms ending in 2029, ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, and approving on an advisory basis the compensation of named executive officers. They will also give an advisory recommendation on how often future say‑on‑pay votes should occur, with the board favoring a one‑year frequency.
Holders of 37,446,534 shares of common stock outstanding as of April 16, 2026 are entitled to vote. The board recommends voting for all director nominees, for auditor ratification, for the say‑on‑pay resolution, and for annual say‑on‑pay frequency.
908 Devices Inc. reported equity compensation grants to Chief Business & Strategy Officer Otitoju Kolawole A. on April 21, 2026. He received 110,193 restricted stock units, each representing one share of common stock, vesting in three substantially equal annual installments on the anniversaries following May 1, 2026, subject to continued service.
He was also granted a stock option for 146,789 shares of common stock at an exercise price of $7.26 per share, expiring on April 20, 2036. One-third of these option shares vest on May 1, 2027, with the remaining two-thirds vesting in substantially equal monthly installments over the following 24 months, contingent on continued service. These are compensation awards rather than open-market purchases or sales.
908 Devices Inc. filed an initial ownership report on Form 3 for Otitoju Kolawole A., who serves as Chief Business & Strategy Officer. This filing establishes his status as an officer and discloses that there are currently no reportable transactions or holdings listed in this statement.
908 Devices Inc. senior vice president Kevin J. McCallion exercised stock options for 2,693 shares of common stock at $1.05 per share and sold the same 2,693 shares at a weighted average price of $7.01 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was pre‑scheduled. Following the transactions, he directly holds 44,925 shares of common stock, and the underlying option grant is now fully exercised.
908 Devices Inc. senior vice president Kevin J. McCallion exercised employee stock options and immediately sold the resulting shares in planned trades. He exercised options for 24,000 shares of common stock at $1.05 per share, then sold 24,000 shares in open-market transactions at weighted-average prices around $7.04 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was scheduled in advance. After these transactions, McCallion directly holds 44,925 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported open-market sales of 40,000 shares of Common Stock. The transactions occurred over three days at prices around $7 per share, under a Rule 10b5-1 trading plan adopted on November 24, 2025.
Brown sold 15,030 shares at a weighted average price of $7.05 on April 8, 7,392 shares at $7.04 on April 9, and 17,578 shares at $7.07 on April 10. After these sales, he continues to hold 945,559 shares directly, indicating he retains a substantial equity position in the company.
Kevin McCallion reported a proposed sale of 27,000 shares of Common Stock via exercise of stock options on 04/08/2026. The filing lists the method as a cash exercise with sales planned through the issuer on NASDAQ. The record also lists prior 10b5-1 sales earlier in 2026 (including 9,438 and 9,000 share transactions).